Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Viracta Therapeutics revenue
Viracta Therapeutics's revenue is $2.1 million.
What is Viracta Therapeutics's revenue?
- Viracta Therapeutics has 26 employees, and the revenue per employee ratio is $79,730.
- Viracta Therapeutics's peak quarterly revenue was $3.5B in 2009(q2).
- Viracta Therapeutics peak revenue was $5.4B in 2008.
- Viracta Therapeutics annual revenue for 2018 was 237.0K, -64.57% growth from 2017.
- Viracta Therapeutics annual revenue for 2019 was 2.1M, 774.68% growth from 2018.
- Viracta Therapeutics's revenue growth from 2004 to 2019 is -79.88%.
On this page
Zippi applies for you, and finds you a job.
Viracta Therapeutics historical revenue
Viracta Therapeutics's peak revenue was $5.4B in 2008. The peak quarterly revenue was $3.5B in 2009(q2).
Viracta Therapeutics's revenue increased from $10.3m in 2004 to $2.1M currently. That's a -79.88% change in annual revenue.
Viracta Therapeutics annual revenue
Viracta Therapeutics annual revenue over time
| Fiscal year / year | Viracta Therapeutics revenue |
|---|---|
| 2009 | $3.8M |
| 2010 | $33,000 |
| 2011 | $5.0M |
| 2012 | $3.8M |
| 2013 | $8.0M |
| 2014 | $5.7M |
| 2015 | $3.1M |
| 2016 | $2.5M |
| 2017 | $669,000 |
| 2018 | $237,000 |
| 2019 | $2.1M |
Rate Viracta Therapeutics' financial transparency
Viracta Therapeutics annual growth
Viracta Therapeutics saw the greatest revenue growth in 2011, when revenue increased by 15,051.52%.
Viracta Therapeutics had the lowest revenue growth in 2010, when revenue changed by -99.12%.
Viracta Therapeutics annual growth rate over time
| Year | Viracta Therapeutics growth |
|---|---|
| 2009 | -100%↓ |
| 2010 | -99%↓ |
| 2011 | 15052%↑ |
| 2012 | -25%↓ |
| 2013 | 112%↑ |
| 2014 | -28%↓ |
| 2015 | -47%↓ |
| 2016 | -17%↓ |
| 2017 | -74%↓ |
| 2018 | -65%↓ |
| 2019 | 775%↑ |
Viracta Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Viracta Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $224.0M | $3.5B | $12.5M | ($3.7B) |
| 2010 | $13,000 | $14,000 | - | $6,000 |
| 2011 | $4.0M | - | $1.0M | - |
| 2012 | - | $1.5M | $265,000 | $2.0M |
| 2013 | $2.0M | $2.0M | $2.0M | $2.0M |
| 2014 | $2.0M | $2.0M | $854,000 | $896,000 |
| 2015 | $854,000 | $854,000 | $683,000 | $670,000 |
| 2016 | $640,000 | $610,000 | $610,000 | $676,000 |
| 2017 | $669,000 | - | - | - |
| 2018 | $237,000 | - | - | - |
Viracta Therapeutics jobs nearby
Do you work at Viracta Therapeutics?
Did Viracta Therapeutics meet its revenue projections?
Viracta Therapeutics financing
Viracta Therapeutics received early financing of $20.0M on 2007-11-02.
| Series | Round size | Date |
|---|---|---|
| Series A | $20M | 11/2007 |
| Series B | $12M | 04/2010 |
| Series Unknown | $6.5M | 03/2012 |
| Series B | $13M | 03/2012 |
| Series B | $18.4M | 04/2017 |
| Corporate Round | $10M | 12/2018 |
| Series E | $40M | 11/2020 |
| Post Ipo Equity | $65M | 02/2021 |
Viracta Therapeutics investors
| Investors | Security type |
|---|---|
| Forward Ventures | Series A |
| Lilly Ventures | Series A |
| De Novo Ventures LLC | Series A |
| Forward Ventures | Series B |
| De Novo Ventures LLC | Series B |
| Lilly Ventures | Series B |
| Aberdare Ventures | Series B |
| Latterell Venture Partners | Series B |
| Forward Ventures | Series B |
| Lilly Ventures | Series B |
| De Novo Ventures LLC | Series B |
| Aberdare Ventures | Series B |
| Latterell Venture Partners | Series B |
| Forward Ventures | Series B |
| NANTKWEST INC | Series B |
| Wicklow Capital Inc | Series B |
| Shenzhen Salubris Pharmaceuticals Co Ltd | Corporate Round |
| Latterell Venture Partners | Series E |
| LifeSci Advisors | Series E |
| aMoon Fund | Series E |
| Taiwania Capital | Series E |
| Serrado Capital | Post Ipo Equity |
| RIDGEBACK CAPITAL MANAGEMENT | Post Ipo Equity |
| BVF PARTNERS L P | Post Ipo Equity |
| LifeSci Advisors | Post Ipo Equity |
| Logos Capital | Post Ipo Equity |
| Sectoral Asset Management | Post Ipo Equity |
| aMoon Fund | Post Ipo Equity |
| Janus Henderson Investors | Post Ipo Equity |
| Samsara BioCapital | Post Ipo Equity |
| Surveyor Capital | Post Ipo Equity |
Search for jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Viracta Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Viracta Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Viracta Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Viracta Therapeutics. The data presented on this page does not represent the view of Viracta Therapeutics and its employees or that of Zippia.
Viracta Therapeutics may also be known as or be related to VIRACTA THERAPEUTICS, INC., Viracta Therapeutics, Viracta Therapeutics Inc, Viracta Therapeutics, INC. and Viracta Therapeutics, Inc.